TRxA BRIDGe Awards: Stage 3

    From Critical Path Institute

    C-Path leads collaborations that accelerate drug development, advancing better treatments for people worldwide.

    Type of Support

    Overview

    The Critical Path Institute's Translational Therapeutics Accelerator (TRxA) is a not-for-profit drug accelerator aimed at helping academic researchers turn new therapeutic ideas into viable drug candidates. This initiative focuses on the early stages of drug development, offering resources, strategic guidance, and engagement with contract research organizations to develop comprehensive data packages essential for attracting biotech and pharmaceutical company investment. TRxA specifically supports projects from early lead optimization through to Investigational New Drug (IND)-enabling studies of small molecule therapeutics, excluding biologics, drug repurposing initiatives, diagnostics, and medical devices. The TRxA BRIDGe Awards target faculty at universities and nonprofit institutions worldwide, without restriction to specific therapeutic areas, covering three stages of drug development from optimization to IND enabling studies.

    Eligibility

    Organization's Location
    qui deserunt
    Program Location
    velit
    Organization Type
    up to 1m

    Submission

    Schedule
    Step 1: aute ut
    Step 2: consectetur ad (excepteur fugiat)